Fostering efficacy of anti-PD-1-treatment: Nivolumab plus radiotherapy in advanced non-small cell lung cancer - study protocol of the FORCE trial
2019-11-08 | journal article
Jump to: Cite & Linked | Documents & Media | Details | Version history
Cite this publication
Fostering efficacy of anti-PD-1-treatment: Nivolumab plus radiotherapy in advanced non-small cell lung cancer - study protocol of the FORCE trial
Bozorgmehr, F.; Hommertgen, A.; Krisam, J.; Lasitschka, F.; Kuon, J.; Maenz, M. & Huber, P. E et al. (2019)
BMC Cancer, 19(1) pp. 1074. DOI: https://doi.org/10.1186/s12885-019-6205-0
Documents & Media
Details
- Authors
- Bozorgmehr, Farastuk; Hommertgen, Adriane; Krisam, Johannes; Lasitschka, Felix; Kuon, Jonas; Maenz, Martin; Huber, Peter E; König, Laila; Kieser, Meinhard; Debus, Juergen; Thomas, Michael; Rieken, Stefan
- Abstract
- Hypofractionated palliative radiotherapy for metastatic lung cancer patients is frequently used in order to ease pain, to increase bone stability, to treat local mass effects, or to prolong progression-free survival at critical sites. Recently introduced, immunotherapy for patients with non-squamous non-small cell lung carcinoma (NSCLC) has significantly improved outcome in this cohort. Preclinical and early clinical data suggest that the combination of photon radiation with programmed death-1 (PD-1) targeting immunotherapies may promote a strong and durable immune response against tumor manifestations both within and beyond radiation targets.
- Issue Date
- 8-November-2019
- Journal
- BMC Cancer
- ISSN
- 1471-2407
- Language
- English
